ASCO 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma - Episode 2

Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER

, , ,

The panelists examine the latest findings from the CheckMate 214 trial, which assessed the combination of nivolumab and ipilimumab (nivo + ipi) as a first-line treatment for advanced renal cell carcinoma, focusing on efficacy, safety, and quality of life outcomes.

EP. 1: Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC
Now Viewing
EP. 2: Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER
EP. 3: Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC
EP. 4: Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials
EP. 5: Exciting Data and Trials in Progress from ASCO 2024
EP. 6: Ongoing RCC Clinical Trials that may Impact Practice
EP. 7: Dr Xu Provides Clinical Perspective on the CONTACT-03 Trial Outcomes
EP. 8: Dr Voss Application of Updated KEYNOTE-564 Data
EP. 9: Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition
EP. 10: World Health Organization (WHO) Classification Updates for Papillary RCC
EP. 11: Additional Forward-Looking Data and Studies Beyond Frontline Therapy in RCC
EP. 12: The Role of Chemotherapy in nccRCC Treatment
EP. 13: Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape
EP. 14: Final Thoughts/Looking Forward
  1. Please briefly discuss the recent data from the CheckMate 214 trial evaluating nivo + ipi for 1L treatment of advanced RCC.
    1. 8-year follow-up and subgroup analyses – please comment on OS, DOR, PFS, TFS, and safety (Tannir et al., ASCO GU 2024 Abstract 363)
    2. What insights do the recent HRQoL data provide? (Cella et al., Oncologist Jan 2024)
  2. Please comment on the role of doublet regimens in the 1L setting for advanced RCC and their recent data updates.
    1. CheckMate 9ER nivo + cabo 
    2. 55-month follow up (Bourlon et al., ASCO GU 2024 Abstract 362)
    3. HRQoL (Bedke et al., ASCO GU 2024 Abstract 384)
    4. Partitioned 4-year OS (Mantia et al., ASCO 2024 Abstract 4507)